LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Book ; Online: Immunotherapy for Tumor in the Brain: Insights From - and For - Other Tumor Sites

    Lampson, Lois A.

    2018  

    Abstract: Tumor immunotherapy has now shown its promise for many, its disappointments and failings for others. Going forward, brain tumor patients can both benefit and contribute.Tumor immunotherapy is steadily progressing. As experience accumulates, it is ... ...

    Abstract Tumor immunotherapy has now shown its promise for many, its disappointments and failings for others. Going forward, brain tumor patients can both benefit and contribute.Tumor immunotherapy is steadily progressing. As experience accumulates, it is important to consider its generality. The reviews herein emphasize the brain's place among other tumor sites. Two major topics are addressed.THE SITE: WHAT CAN WE EXPECT FROM IMMUNOTHERAPY WHEN THE TARGET IS IN THE BRAIN?Experience with immunotherapy for different targets in the brain, including tumor and also pathogens, is reviewed. Long-standing assumptions are confronted. The potential for beneficial responses is stressed.BRAIN TUMOR IMMUNOTHERAPY: WHAT HAVE WE LEARNED SO FAR?Clinical experience with brain tumor immunotherapy, from a variety of centers, is reviewed. Primary tumors, emphasizing glioblastoma, and brain metastases are each considered
    Keywords Medicine (General) ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    Size 1 electronic resource (95 p.)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT020101849
    ISBN 9782889455355 ; 2889455351
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article: Editorial: Immunotherapy for Tumor in the Brain: Insights From-and For-Other Tumor Sites.

    Lampson, Lois A

    Frontiers in oncology

    2018  Volume 8, Page(s) 128

    Language English
    Publishing date 2018-04-27
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2018.00128
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Brain tumor immunotherapy: seeing the brain in the body.

    Lampson, Lois A

    Drug discovery today

    2013  Volume 18, Issue 7-8, Page(s) 399–406

    Abstract: Brain tumor immunotherapy is often interpreted in terms of immune privilege and the blood-brain barrier (BBB), but a broader view is warranted. The delicate regulatory balance of the immune system is relevant at any site, as are the heterogeneity and ... ...

    Abstract Brain tumor immunotherapy is often interpreted in terms of immune privilege and the blood-brain barrier (BBB), but a broader view is warranted. The delicate regulatory balance of the immune system is relevant at any site, as are the heterogeneity and plasticity of tumor growth. Criteria for tumor antigens, and often the antigens themselves, cut across tumor types. Here, this broader view, complemented by current understanding of privilege and the BBB, provides the context for review. Future success is likely to exploit simplified methods, used in combination; and similarities - more than differences - between the brain and other sites.
    MeSH term(s) Animals ; Antigens, Neoplasm/immunology ; Brain Neoplasms/immunology ; Brain Neoplasms/therapy ; Humans ; Immunotherapy
    Chemical Substances Antigens, Neoplasm
    Language English
    Publishing date 2013-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/j.drudis.2012.11.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

    Lampson, Lois A

    mAbs

    2011  Volume 3, Issue 2, Page(s) 153–160

    Abstract: Monoclonal antibodies (mAbs) are used with increasing success against many tumors but, for brain tumors, the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is ... ...

    Abstract Monoclonal antibodies (mAbs) are used with increasing success against many tumors but, for brain tumors, the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is more complex. The BBB is closest to normal at micro-tumor sites; its properties and importance change as the tumor grows. In this review, evolving insight into the role of the BBB is balanced against other factors that affect efficacy or interpretation when mAbs are used against brain tumor targets. As specific examples, glioblastoma multiforme (GBM), primary central nervous system lymphoma (PCNSL) and blood-borne metastases from breast cancer are discussed in the context of treatment, respectively, with the mAbs bevacizumab, rituximab, and trastuzumab, each of which is already widely used against tumor outside the brain. It is suggested that success against brain tumors will require getting past the BBB in two senses: physically, to better attack brain tumor targets and conceptually, to give equal attention to problems that are shared with other tumor sites.
    MeSH term(s) Antibodies, Monoclonal/physiology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Biological Transport ; Blood-Brain Barrier/physiology ; Brain Neoplasms/blood supply ; Brain Neoplasms/therapy ; Glioblastoma/blood supply ; Glioblastoma/therapy ; Humans ; Lymphoma, Non-Hodgkin/therapy ; Trastuzumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2011-03-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2537838-7
    ISSN 1942-0870 ; 1942-0870
    ISSN (online) 1942-0870
    ISSN 1942-0870
    DOI 10.4161/mabs.3.2.14239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Targeted therapy for neuro-oncology: reviewing the menu.

    Lampson, Lois A

    Drug discovery today

    2009  Volume 14, Issue 3-4, Page(s) 185–191

    Abstract: Targeted therapy against cancer shows not only promise, but also limits. No matter how specific the target, many pathways and cell types can be affected, some unexpectedly. A tumor is heterogeneous and plastic; it can evade a targeting agent or an attack ...

    Abstract Targeted therapy against cancer shows not only promise, but also limits. No matter how specific the target, many pathways and cell types can be affected, some unexpectedly. A tumor is heterogeneous and plastic; it can evade a targeting agent or an attack mechanism. Local regulatory factors contribute to site-specific effects. In the brain, widely disseminated tumor, including microscopic tumor; local regulatory differences and impediments to brain-wide delivery can all limit the efficacy of any single agent or approach. Provocatively, precedents for both problems and solutions are seen in the original targeted therapy, the immune response.
    MeSH term(s) Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Brain Neoplasms/drug therapy ; Brain Neoplasms/immunology ; Brain Neoplasms/physiopathology ; Clinical Trials as Topic ; Drug Delivery Systems ; Humans
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2009-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/j.drudis.2008.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Brain tumor immunotherapy: an immunologist's perspective.

    Lampson, Lois A

    Journal of neuro-oncology

    2003  Volume 64, Issue 1-2, Page(s) 3–11

    Abstract: Key concepts in brain tumor immunotherapy are reviewed. "Immunotherapy" can refer to a fully-developed, tumor-specific immune response, or to its individual cellular or molecular mediators. The immune response is initiated most efficiently in organized ... ...

    Abstract Key concepts in brain tumor immunotherapy are reviewed. "Immunotherapy" can refer to a fully-developed, tumor-specific immune response, or to its individual cellular or molecular mediators. The immune response is initiated most efficiently in organized lymphoid tissue. After initiation, antigen-specific T lymphocytes (T cells) survey the tissues--including the brain. If the T cells re-encounter their antigen at a tumor site, they can be triggered to carry out their effector functions. T cells can attack tumor in many ways, directly and indirectly, through cell-cell contact, secreted factors, and attraction and activation of other cells, endogenous or blood-borne. Recent work expands the list of candidate tumor antigens: they are not limited to cell surface proteins and need not be absolutely tumor-specific. Once identified, tumor antigens can be targeted immunologically, or in novel ways. The immune response is under complex regulatory control. Most current work aims to enhance initiation of the response (for example, with tumor vaccines), rather than enhancing the effector phase at the tumor site. The effector phase includes a rich, interactive set of cells and mediators; some that are not usually stressed are of particular interest against tumor in the brain. Within the brain, immune regulation varies from site to site, and local neurochemicals (such as substance P or glutamate) can contribute to local control. Given the complexity of a tumor, the brain, and the immune response, animal models are essential, but more emphasis should be given to their limitations and to step-by-step analysis, rather than animal "cures".
    MeSH term(s) Animals ; Antibody Formation ; Antigens, Neoplasm/immunology ; Brain Neoplasms/immunology ; Brain Neoplasms/therapy ; Cancer Vaccines/therapeutic use ; Disease Models, Animal ; Genetic Therapy ; Humans ; Immunologic Techniques ; Immunotherapy
    Chemical Substances Antigens, Neoplasm ; Cancer Vaccines
    Language English
    Publishing date 2003-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604875-4
    ISSN 1573-7373 ; 0167-594X
    ISSN (online) 1573-7373
    ISSN 0167-594X
    DOI 10.1007/bf02700015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1825: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Molecular bases of the immune response to neural antigens

    Lampson, Lois A.

    Trends Neurosci

    Abstract: Long-standing ideas about the immune response to neural antigens can now be revised. While the brain may be ‘immunologically privileged’, the privilege is not absolute; both immune and autoimmune responses can occur. While the blood-brain barrier ... ...

    Abstract Long-standing ideas about the immune response to neural antigens can now be revised. While the brain may be ‘immunologically privileged’, the privilege is not absolute; both immune and autoimmune responses can occur. While the blood-brain barrier contributes to this immunological isolation, other factors are also important. One is the normal absence of products of the major histocompatibility complex (MHC) from neural tissue. Without these cell surface proteins, neural cells are protected from T cell-mediated immune surveillance. MHC expression and modulation in neural tissue, and the implications for understanding and control of the immune response to neural antigens, are reviewed below.
    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1016/0166-2236(87)90153-6
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains.

    Dutta, Tanya / Spence, Alexander / Lampson, Lois A

    Journal of neuro-oncology

    2003  Volume 64, Issue 1-2, Page(s) 31–44

    Abstract: T cells are attractive for delivering therapy to brain tumor, especially disseminated micro-tumor. However, to trigger effector function, tumor antigen must be re-presented to T cells, via major histocompatibility complex (MHC) proteins, at the tumor ... ...

    Abstract T cells are attractive for delivering therapy to brain tumor, especially disseminated micro-tumor. However, to trigger effector function, tumor antigen must be re-presented to T cells, via major histocompatibility complex (MHC) proteins, at the tumor site. In normal brain, MHC+ antigen-presenting cells (APC) are rare, but abundant after gamma interferon (IFN-gamma) injection. Here we studied tumor-bearing brains. IFN-gamma (or buffer) was injected stereotactically into brains with established tumors from a panel of immunologically varied glioma cell lines, some expressing b-galactosidase as a micro-tumor marker. Four days later, cryostat sections were stained for tumor and MHC proteins. In phosphate-buffered saline-injected controls, class II MHC+ potential APC (microglia, macrophages) were seen only at (some) tumor sites. In rats that received IFN-gamma, class II+ potential APC were widespread, including all actual and potential micro-tumor sites and all tumor-free areas. In the same slides, neither class I nor class II MHC antigen was detected in neural cells or most tumor cells. This MHC pattern favors indirect re-presentation of tumor antigen, by tumor-adjacent APC. The robust response to IFN-gamma might also be exploited in other ways: activated microglia and macrophages can attack tumor directly, and class II+ APC may help mark micro-tumor sites.
    MeSH term(s) Animals ; Brain/metabolism ; Brain/pathology ; Brain Neoplasms/immunology ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Histocompatibility Antigens Class II/metabolism ; Imaging, Three-Dimensional ; Injections ; Interferon-gamma/administration & dosage ; Interferon-gamma/pharmacology ; Male ; Rats ; Rats, Inbred Strains ; Up-Regulation
    Chemical Substances Histocompatibility Antigens Class II ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2003-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604875-4
    ISSN 1573-7373 ; 0167-594X
    ISSN (online) 1573-7373
    ISSN 0167-594X
    DOI 10.1007/bf02700018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1825: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Molecular bases of the immune response to neural antigens

    Lampson, Lois A.

    Trends in Neurosciences

    Abstract: Abstract Long-standing ideas about the immune response to neural antigens can now be revised. While the brain may be ‘immunologically privileged’, the privilege is not absolute; both immune and autoimmune responses can occur. While the blood-brain ... ...

    Abstract Abstract Long-standing ideas about the immune response to neural antigens can now be revised. While the brain may be ‘immunologically privileged’, the privilege is not absolute; both immune and autoimmune responses can occur. While the blood-brain barrier contributes to this immunological isolation, other factors are also important. One is the normal absence of products of the major histocompatibility complex (MHC) from neural tissue. Without these cell surface proteins, neural cells are protected from T cell-mediated immune surveillance. MHC expression and modulation in neural tissue, and the implications for understanding and control of the immune response to neural antigens, are reviewed below.
    Keywords covid19
    Publisher Elsevier
    Document type Article ; Online
    DOI 10.1016/0166-2236(87)90153-6
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Increased CDK1 activity determines the timing of kinetochore-microtubule attachments in meiosis I.

    Davydenko, Olga / Schultz, Richard M / Lampson, Michael A

    The Journal of cell biology

    2013  Volume 202, Issue 2, Page(s) 221–229

    Abstract: ... indicate that the slow increase in CDK1 activity in meiosis I acts as a timing mechanism to allow stable K ...

    Abstract Chromosome segregation during cell division depends on stable attachment of kinetochores to spindle microtubules. Mitotic spindle formation and kinetochore-microtubule (K-MT) capture typically occur within minutes of nuclear envelope breakdown. In contrast, during meiosis I in mouse oocytes, formation of the acentrosomal bipolar spindle takes 3-4 h, and stabilization of K-MT attachments is delayed an additional 3-4 h. The mechanism responsible for this delay, which likely prevents stabilization of erroneous attachments during spindle formation, is unknown. Here we show that during meiosis I, attachments are regulated by CDK1 activity, which gradually increases through prometaphase and metaphase I. Partial reduction of CDK1 activity delayed formation of stable attachments, whereas a premature increase in CDK1 activity led to precocious formation of stable attachments and eventually lagging chromosomes at anaphase I. These results indicate that the slow increase in CDK1 activity in meiosis I acts as a timing mechanism to allow stable K-MT attachments only after bipolar spindle formation, thus preventing attachment errors.
    MeSH term(s) Anaphase ; Animals ; Aurora Kinases ; CDC2 Protein Kinase/genetics ; CDC2 Protein Kinase/metabolism ; Chromosome Segregation ; Chromosomes, Mammalian/genetics ; Chromosomes, Mammalian/metabolism ; Enzyme Activation ; Female ; Kinetochores/metabolism ; Meiosis ; Metaphase ; Mice ; Microtubules/genetics ; Microtubules/metabolism ; Oocytes/cytology ; Oocytes/metabolism ; Prometaphase ; Protein Binding ; Protein-Serine-Threonine Kinases/genetics ; Protein-Serine-Threonine Kinases/metabolism ; Spindle Apparatus/genetics ; Spindle Apparatus/metabolism ; Time Factors
    Chemical Substances Aurora Kinases (EC 2.7.11.1) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1) ; CDC2 Protein Kinase (EC 2.7.11.22)
    Language English
    Publishing date 2013-07-15
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 218154-x
    ISSN 1540-8140 ; 0021-9525
    ISSN (online) 1540-8140
    ISSN 0021-9525
    DOI 10.1083/jcb.201303019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ub I Zs.190: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top